May 26, 2008 - Intas Biopharmaceuticals Limited is all set to market Lung Cancer drug, GEFITINIB, under brand name "GEFFY", in Indian market. In line with company's sales strategy to market novel targeted therapies, Intas Biopharmaceuticals will market GEFFY for treatment of Lung cancer especially non-small cell lung cancer (NSCLC). The new drug GEFFY is a class of anti-cancer medications called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply.
The details can be read here.
No comments:
Post a Comment